Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$32.10 – $39.19
87% from low
Exchange
ARCX
ETF
Borrow rate
9.66%
Hard to borrow
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| APIEActivePassive International Equity ETF | $38.30 | +0.90% | $1.1B | — |
| APCBActivePassive Core Bond ETF | $29.51 | +0.14% | $937M | — |
| EIPIFT Energy Income Partners Enhanced Income ETF | $21.97 | -0.41% | $1.1B | — |
| FXHFirst Trust Health Care AlphaDEX Fund | $122.89 | -0.02% | $875M | — |
| HAUZXtrackers International Real Estate ETF |
No company description on file.
No one on the platform currently holds APIE.
No tracked institution reports a position in APIE as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-12-23 | $1.3185 | 2025-12-24 |
| 2024-12-23 | $0.5993 | 2024-12-24 |
| 2023-12-26 | $0.1670 | 2023-12-28 |
No one on the platform has traded APIE yet.
| $22.57 |
| +0.45% |
| $1.1B |
| — |
| PSCPrincipal U.S. Small-Cap Multi-Factor ETF | $69.38 | +0.38% | $1.2B | — |
| QEFAState Street SPDR MSCI EAFE StrategicFactors ETF | $96.08 | +0.95% | $1.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Novo Nordisk To Launch Ozempic Pills Following Flat Growth In Diabetes Segment In 2025 $NVO $DFAX $APIE https://stocktwits.com/news/equity/markets/novo-nordisk-to-launch-ozempic-pills-following-flat-growth-in-diabetes-segment-in-2025/cZbjiusR4Ni
View on StockTwits ↗Novo Nordisk Shares Tumble On Q4 Miss, Weak Sales Forecast And Competition Concerns $NVO $DFAX $APIE https://stocktwits.com/news/equity/markets/novo-nordisk-shares-tumble-on-q4-miss-weak-sales-forecast/cZbi6tLR4m0
View on StockTwits ↗Novo Nordisk Inks Deal With Canada’s Aspect Biosystems To Find More Diabetes Meds Besides Ozempic $NVO $DFAX $APIE https://stocktwits.com/news/equity/markets/novo-nordisk-inks-deal-with-canada-aspect-biosystems-to-find-more-diabetes-meds/cmUuDZyR4OW
View on StockTwits ↗Ryanair Pulls Plug On Prime Membership Offering After Trial Proves Too Costly $RYAAY $APIE $CGGR https://stocktwits.com/news/equity/markets/ryanair-pulls-plug-on-prime-membership-offering-after-trial-proves-too-costly/cL5aRnaRELJ
View on StockTwits ↗Novo Nordisk’s Experimental GLP-1 Drug Shows Weight Loss, Blood Sugar Levels Reduction In Study $NVO $DFAX $APIE https://stocktwits.com/news/equity/markets/novo-nordisk-experimental-glp-1-drug-shows-weight-loss-blood-sugar-level-reduction-in-study/cL52hCvREXo
View on StockTwits ↗Novo Nordisk’s Blockbuster Drug Fails To Slow Alzheimer’s Disease Progression In Studies $NVO $DFAX $APIE https://stocktwits.com/news/equity/markets/novo-nordisk-blockbuster-drug-fails-to-slow-alzheimers-disease-progression-in-studies/cL5bIRrREQT
View on StockTwits ↗Why Did BioNTech Stock Surge 10% Pre-Market Today? $BNTX $APIE $TCAF https://stocktwits.com/news/equity/markets/why-is-biontech-rising-pre-market-today/chwIXnPRdqb
View on StockTwits ↗Sanofi’s New Experimental Eczema Drug Meets Goals Of Late-stage Trial, But Wall Street Expected More $SNY $DFAX $APIE https://stocktwits.com/news/equity/markets/sanofi-experimental-eczema-drug-meets-goals-of-late-stage-trial/chwddprRdYk
View on StockTwits ↗Novartis Fails To Block Heart Failure Drug’s Generic From Launching Through 2026: Report $NVS $DFAX $APIE https://stocktwits.com/news/equity/markets/novartis-fails-to-block-heart-failure-drugs-generic-from-launching-through-2026-report/ch8cmAbR5Ne
View on StockTwits ↗Novartis Gets Swiss Authority Nod For First Malaria Drug In Newborns, Young Infants $NVS $DFAX $APIE https://stocktwits.com/news/equity/markets/novartis-gets-swiss-authority-nod-for-first-malaria-drug-in-newborns-young-infants/chFvYaxR5gZ
View on StockTwits ↗Novartis’ Blockbuster Drug Fails Late-Stage Trial In Disease Causing Blood Vessel Inflammation, But Retail Turns Bullish $NVS $DFAX $APIE https://stocktwits.com/news/equity/markets/novartis-drug-fails-late-stage-trial-in-disease-causing-blood-vessel-inflammation/chFjsnERcNX
View on StockTwits ↗US Judge Upholds FDA Decision To Remove Wegovy, Ozempic From Shortage List In Move Against Compounding Pharmacies $NVO $AVDE $APIE https://stocktwits.com/news/equity/markets/us-judge-upholds-fda-decision-to-remove-wegovy-ozempic-from-shortage-list/chlsO9tRR20
View on StockTwits ↗Novo Nordisk’s Plan To Start Late-Stage Trial Of Investigational Obesity Drug Amycretin In 2026 Gets Retail Talking $NVO $AVDE $APIE https://stocktwits.com/news/equity/markets/novo-nordisk-to-start-late-stage-trial-of-investigational-obesity-drug-in-2026/chlg4jxRRG7
View on StockTwits ↗Mesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’ $MESO $APIE $IBBQ https://stocktwits.com/news/equity/markets/mesoblast-gives-positive-update-about-potential-fda-application-for-revascor/chlgT5lRb6z
View on StockTwits ↗Novo Nordisk’s $812M Deal With Deep Apple Lifts Retail Mood, Chatter Spikes To High Levels $NVO $AVDE $APIE https://stocktwits.com/news/equity/markets/novo-nordisk-inks-812-million-deal-wth-deep-apple-therapeutics/chlaHHKRbCH
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.